Download PDFPDF

Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Reply to the author: Charles Bonnet Syndrome

    Dear Editor

    I thank Dr Tomsak for his reply[1] to my comments.[2]

    In response to point one,we agree that historically CBS is a disorder described in the elderly, but as we mentioned in our previous reply, this can easily be explained by the higher incidence of visual loss in the elderly. Further, without formal child pyschiatry review it is difficult to give a incidence in the childhood of CBS. As you wo...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Charles Bonnet Syndrome - Author reply

    Dear Editor

    I thank Dr Rahman and his colleagues for their comments.

    1. Clinically and historically Charles Bonnet Syndrome (CBS) is indeed a disorder of the elderly, in spite of rare reports of the syndrome in young patients.

    2. Space constraints imposed by editorial considerations prevented us from discussing the nuances of CBS in detail. But, we state quite clearly in the first sentence...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Charles Bonnet Syndrome and brimonidine: comments
    • Imran Rahman, Ophthalmologist
    • Other Contributors:
      • Bertie S Fernando, Maggie Harrison

    Dear Editor

    We read, with interest the article 'Charles Bonnet Syndrome precipitated by Brimonidine Tartrate eye drops' published in July 2003 BJO. Interest in Charles-Bonnet syndrome (CBS) has escalated of late, highlighting the probable 15% [1] incidence of the condition in patients with significant visual impairment coupled with a clear sensorium.

    The authors implied that CBS was induced in 4 patient...

    Show More
    Conflict of Interest:
    None declared.